Using in vitro and in vivo models for bladder cancer, we have recently found that ELK1 activation correlates with the induction of cell proliferation, migration, and invasion, as well as resistance to cisplatin cytotoxicity [10,11]. Here, ELK1 is linked to urinary bladder cancer.